By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Hims & Hers Health is betting that the cash ... Sustainabilitycategory· June 9, 2025 Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports Activist hedge fund Parvus Asset ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...